gvs 111 has been researched along with Alzheimer Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gudasheva, TA; Kuzmina, USh; Ostrovskaya, RU; Salimgareeva, MKh; Seredenin, SB; Vakhitov, VA; Vakhitova, YV; Zainullina, LF | 1 |
| Belnik, AP; Ostrovskaya, RU; Storozheva, ZI | 1 |
| Iamidanov, RS; Ostrovskaia, RU; Salimgareeva, MKh; Tsaplina, AP; Vakhitova, IuV | 1 |
| Bobkova, NA; Gruden, MA; Gudasheva, TA; Morozova-Roche, LA; Noppe, W; Ostrovskaya, RU; Samokhin, AN; Seredinin, SB; Sewell, RD; Sherstnev, VV | 1 |
4 other study(ies) available for gvs 111 and Alzheimer Disease
| Article | Year |
|---|---|
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cell Survival; Dipeptides; Disease Models, Animal; Humans; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Phosphorylation; Rats; tau Proteins | 2014 |
Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Basal Nucleus of Meynert; Dipeptides; Disease Models, Animal; Humans; Male; Memory Disorders; Nootropic Agents; Peptide Fragments; Random Allocation; Rats; Rats, Wistar | 2008 |
[Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats].
Topics: Alzheimer Disease; Animals; Avoidance Learning; Brain; Dipeptides; Male; Malondialdehyde; Memory; Nerve Growth Factors; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Rats; Streptozocin | 2010 |
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoantibodies; Behavior, Animal; Dipeptides; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Memory; Mice; Microscopy, Atomic Force; Muramidase; Nerve Growth Factors; Neuroprotective Agents; Nootropic Agents; Olfactory Bulb; Peptide Fragments; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Space Perception; Time Factors | 2007 |